REVERSAL OF ESTABLISHED FELINE LEUKEMIA VIRUS INFECTION AFTER ADOPTIVE TRANSFER OF ACTIVATED LYMPHOCYTES IN COMBINATION WITH AZIDOTHYMIDINE AND ALPHA INTERFERON (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

REVERSAL OF ESTABLISHED FELINE LEUKEMIA VIRUS INFECTION AFTER ADOPTIVE TRANSFER OF ACTIVATED LYMPHOCYTES IN COMBINATION WITH AZIDOTHYMIDINE AND ALPHA INTERFERON (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2358 1992. Unique Identifier : AIDSLINE ICDB/92684459
Zeidner NS; Mathiason-DuBard CK; Hoover EA; Dept. of Pathology, Colorado State Univ., Fort Collins, CO 80523

Abstract: The treatment of FeLV-FAIDS viremia utilizing IFN alpha, alone or in combination with AZT, resulted in a significant reduction in circulating virus load. However, the antiviral effect of IFN alpha was limited by the production of antibodies to IFN alpha, detected 7 wk after the start of therapy. To examine the hypothesis that combination treatment consisting of immune reconstitution plus chemotherapy would induce reversal of established retrovirus infection, cats were infused with activated lymphocytes, IFN alpha, and AZT 12 wk after infection with FeLV-FAIDS. Recipient cats received 1.45 x 10(8) lymphocytes weekly and viremia was reversed in 4 of 6 cats after 5 adoptive cell transfers. These cats remained negative for circulating virus during a 63-day treatment period, despite the elaboration of anti-IFN alpha antibodies. Development of virus neutralizing antibody, specific for the virus envelope, was detected only in those cats which reversed retroviremia; 3 of 6 treated cats remained negative for FeLV antigen 95 days after treatment was discontinued. Therapy employing lymphocyte infusion alone failed to influence the course of established FeLV-FAIDS infection. These results suggest that combination therapy utilizing IFN alpha and adoptive lymphocyte transfer served to reconstitute humoral immunity, counteract retrovirus-induced immune suppression and induce reversal of established retroviremia.

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Animal Antibody Formation Antigens, Viral/ANALYSIS Cats *Immunotherapy, Adoptive Interferon-alpha/IMMUNOLOGY/*THERAPEUTIC USE Killer Cells, Lymphokine-Activated/*IMMUNOLOGY/TRANSPLANTATION Leukemia Virus, Feline/IMMUNOLOGY/*PATHOGENICITY Leukemia, Feline/IMMUNOLOGY/*THERAPY Zidovudine/*THERAPEUTIC USE ABSTRACT
920930
M9290910

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .